XML 36 R26.htm IDEA: XBRL DOCUMENT v3.24.3
Stock-Based Compensation (Tables)
9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Fair Value of Options
The fair value of the stock options granted were estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:
 Three Months Ended September 30,Nine Months Ended September 30,
 2024202320242023
Expected stock price volatility55.5 %58.4 %57.1 %59.2 %
Risk free interest rate3.9 %4.3 %4.0 %3.9 %
Expected life of options (years)5.65.55.65.5
Expected annual dividend per share$— $— $— $— 
Schedule of Stock Options Activity A summary of the Company's stock options for the nine months ended September 30, 2024 were as follows:
Number of
Shares
Weighted Average Exercise 
Price
Weighted Average Remaining
Years
Aggregate
Intrinsic
Value
 (in thousands)  (in millions)
Options outstanding, December 31, 202323,002 $11.69   
Granted4,693 $13.69   
Exercised(791)$7.74   
Forfeited(548)$12.74   
Expired(217)$14.58 
Options outstanding, September 30, 202426,139 $12.12 6.0$13.6 
Vested and non-vested expected to vest, September 30, 202424,610 $12.09 5.9$13.5 
Exercisable at September 30, 202417,092 $11.75 4.7$13.0 
Schedule of Non-Vested RSU Activity under the Plan A summary of non-vested RSU activity under the Plan for the nine months ended September 30, 2024 is as follows:
Number of
Shares
Weighted
Average Grant
Date Fair
Value
Weighted 
Average
Remaining 
Years
Aggregate
Intrinsic
Value
(in thousands)(in millions)
Non-vested units as of December 31, 202310,033 $13.37   
Granted3,893 $14.63   
Vested(3,860)$13.17   
Forfeited(613)$14.28   
Non-vested units as of September 30, 20249,453 $13.82 2.2$101.0 
Schedule of Equity Compensation Expenses
The following table summarizes information related to compensation expense recognized in the Company's Consolidated Statements of Operations related to the equity awards:
 Three Months Ended September 30,Nine Months Ended September 30,
(in thousands)2024202320242023
Research and development expense$4,397 $4,380 $12,329 $16,987 
Selling, general, and administrative expense14,291 12,131 53,359 50,995 
Total equity compensation expense$18,688 $16,511 $65,688 $67,982